1. Home
  2. WIA vs EDIT Comparison

WIA vs EDIT Comparison

Compare WIA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Inflation-Linked Income Fund

WIA

Western Asset Inflation-Linked Income Fund

HOLD

Current Price

$8.25

Market Cap

192.4M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.38

Market Cap

202.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIA
EDIT
Founded
2003
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.4M
202.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
WIA
EDIT
Price
$8.25
$2.38
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.50
AVG Volume (30 Days)
39.2K
1.9M
Earning Date
01-01-0001
03-04-2026
Dividend Yield
12.29%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$46,383,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.56
$0.91
52 Week High
$8.91
$4.54

Technical Indicators

Market Signals
Indicator
WIA
EDIT
Relative Strength Index (RSI) 42.04 58.00
Support Level $8.20 $1.92
Resistance Level $8.29 $2.43
Average True Range (ATR) 0.04 0.14
MACD 0.00 0.05
Stochastic Oscillator 8.33 91.15

Price Performance

Historical Comparison
WIA
EDIT

About WIA Western Asset Inflation-Linked Income Fund

Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: